Eupraxia Pharmaceuticals is trading 19.4% higher at $9.25 in pre-market on October 6, 2026; no company announcement is listed for October 5 or 6.
- Shares also gained 6.98% in the October 5 session.
- The latest release, on September 30, reported 52-week trial data, including remission maintained by 66% of patients in the highest-dose cohort. Available evidence does not establish that this earlier news caused the current move.